REGENXBIO Cash on Hand 2014-2022 | RGNX
REGENXBIO cash on hand from 2014 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
REGENXBIO Annual Cash on Hand
(Millions of US $) |
| 2021 |
$457 |
| 2020 |
$476 |
| 2019 |
$296 |
| 2018 |
$320 |
| 2017 |
$161 |
| 2016 |
$90 |
| 2015 |
$114 |
| 2014 |
$1 |
| 2013 |
$1 |
REGENXBIO Quarterly Cash on Hand
(Millions of US $) |
| 2022-03-31 |
$394 |
| 2021-12-31 |
$457 |
| 2021-09-30 |
$340 |
| 2021-06-30 |
$375 |
| 2021-03-31 |
$441 |
| 2020-12-31 |
$476 |
| 2020-09-30 |
$242 |
| 2020-06-30 |
$269 |
| 2020-03-31 |
$279 |
| 2019-12-31 |
$296 |
| 2019-09-30 |
$332 |
| 2019-06-30 |
$341 |
| 2019-03-31 |
$285 |
| 2018-12-31 |
$320 |
| 2018-09-30 |
$373 |
| 2018-06-30 |
$286 |
| 2018-03-31 |
$230 |
| 2017-12-31 |
$161 |
| 2017-09-30 |
$167 |
| 2017-06-30 |
$162 |
| 2017-03-31 |
$146 |
| 2016-12-31 |
$90 |
| 2016-09-30 |
$92 |
| 2016-06-30 |
$94 |
| 2016-03-31 |
$101 |
| 2015-12-31 |
$114 |
| 2015-09-30 |
$213 |
| 2015-06-30 |
|
| 2015-03-31 |
|
| 2014-12-31 |
|
| 2014-09-30 |
|
| 2013-12-31 |
$1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.106B |
$0.470B |
|
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
|
